A randomized, double-blind, placebo-controlled Phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer
Evaluate progression-free survival in patients with metastatic triple-negative breast cancer treated with the combination of paclitaxel and oral reparixin compared to paclitaxel alone.
Clinical Trial Categories
Stephanie Porenta: 425.467.3986, Stephanie.Porenta@overlakehospital.org
Overlake Medical Center
1035 116th Ave. NE
Bellevue, WA 98004